Saving changes...



Metronomic Chemotherapy in Veterinary Oncology

Metronomic Chemotherapy in Veterinary Oncology

Metronomic Chemotherapy in Veterinary Oncology

Veterinary Cancer Society
Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association


$12.50 $ 12.50 $ 12.50

12.50 $ 12.50 12.50 12.50
Normal Price: FREE $12.50


Launch date: 15 Apr 2015
Expiry Date:

Last updated: 27 Aug 2018

Reference: 150689

TIming: null

Maximum Attendees:

Places Left: 0

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.


Continuous administration of comparatively low doses of cytotoxic chemotherapy, known as "metronomic" therapy, may represent a more targeted approach to cancer treatment than conventional chemotherapy protocols. Metronomic chemotherapy can inhibit tumor blood supply (anti-angiogenesis), stimulate anti-tumoral immunity, and possibly impact cancer-initiating cells, in addition to having direct cancer cell killing effects. While most mechanistic and efficacy studies have been laboratory-based, clinical evaluation of this treatment approach using a variety of chemotherapy drugs is becoming more common. These treatment protocols are generally well tolerated, however the potential efficacy and long term side effects have yet to be fully evaluated. This presentation will review the mechanistic and clinical trials of metronomic chemotherapy in veterinary oncology and highlight the potential for integration of this strategy with the use of other targeted oncology drugs in practice.


Conventional dose and scheduling of chemotherapy has generally followed the principle of maximum tolerated dose (MTD), which is defined by the highest allowable toxicity to rapidly dividing normal tissues, such as cells in the bone marrow and intestinal epithelium. Because of this schedule, there is an unavoidable break period between doses to allow for repair of these cells. In veterinary oncology high-grade toxicity is not an acceptable component of treatment and doses are adjusted accordingly
Veterinary Cancer Society

Author Information Play Video Bio

Veterinary Cancer Society
on behalf of Missouri Veterinary Medical Association

Dr. Tony Mutsaers graduated from the Ontario Veterinary College in 1997. Following a year of private practice in Newcastle Ontario he returned to OVC for a rotating internship in small animal medicine and surgery, followed by a residency in Oncology at Purdue University. He is a Diplomate of the American College of Veterinary Internal Medicine in Oncology. After his residency Tony worked as a clinical instructor at the University of Queensland in Brisbane, Australia. He then returned to Canada to study biomarkers for targeted oncology drugs at the Sunnybrook Research Institute, culminating in a PhD from the University of Toronto. During his graduate studies he practiced part-time as a medical oncologist at OVC, and was an Adjunct Professor with the Department of Clinical Studies from 2007 – 2010. He then completed a post-doctoral fellowship at the St Vincent’s Institute of Medical Research in Melbourne, Australia studying osteosarcoma. In 2011 Tony became an Assistant Professor at the University of Guelph with a joint appointment in the Departments of Clinical Studies and Biomedical Sciences.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 0.50 Hours -
    Exam Attempts: 3
    Exam Pass Rate: 60

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:


User Reviews (0)

Go Back


Saving changes...